17.06.2015 • NewsAkzoNobelchlor-alkaliChlorine

Evonik and AkzoNobel in Electroysis JV

Germany’s Evonik and AkzoNobel of the Netherlands have established a 50:50...
Germany’s Evonik and AkzoNobel of the Netherlands have established a 50:50 joint venture to build and operate a membrane electrolysis facility for potassium hydroxide solution and chlorine at AkzoNobel’s Ibbenbüren, Germany, site

Germany’s Evonik and AkzoNobel of the Netherlands have established a 50:50 joint venture to build and operate a membrane electrolysis facility for potassium hydroxide solution and chlorine at AkzoNobel’s Ibbenbüren, Germany, site. The facility, due to start up in the fourth quarter of 2017, will have a nameplate capacity for 130,000 t/y of potassium hydroxide solution and a 82,000 t/y of chlorine.

AkzoNobel will process the chlorine and the hydrogen output directly at the site and market the remainder on the open market, while Evonik will market or further process the potassium hydroxide solution into potassium carbonate at its Lülsdorf, Germany site.

The new joint venture will enable Evonik to supply customers with our potassium derivatives reliably in the long term and also make a “significant contribution” to environmentally-friendly and sustainable production of potassium derivatives, said Evonik exeutive board member Patrik Wohlhauser.

Werner Fuhrmann, AkzoNobel’s executive committee member responsible for specialty chemicals, said the Dutch company’s investment in its
chlor-alkali activities will make its business “even more sustainable.”

Under an EU directive, production of chlorine, potassium hydroxide and sodium hydroxide solutions using mercury electrolysis must be phased out by 2018.

The two companies said the jv – still subject to regulatory clearance – will serve to further strengthen their respective leading market positions.
 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
10.02.2025 • News

Johnson Matthey, Bosch to Partner on Hydrogen Technology

UK sustainable technologies group Johnson Matthey (JM) and German engineering giant Bosch have agreed on a long-term collaboration to develop and produce high-performance catalyst-coated membranes (CCMs) for use in hydrogen fuel cells.

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.